In a six-month open-label extension of the six-month double-blind study, ADAS-cog scores were maintained at baseline following 12 months of treatment with 24 mg/day galantamine. This treatment group performed significantly better on cognitive measurements than patients who received placebo during the six-month double-blind study and then were treated with galantamine (24 mg/day) during the six-month open-label phase.